Novo Nordisk

Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections
Novo backs 'breakthrough' antifungal player's $60M round — with a focus on rare mold infections
Endpoints
drug development
antibiotics
F2G
Novo Nordisk
Flag link:
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes
Pharmaforum
Novo Nordisk
diabetes
digital pharma
digital medicine
Flag link:
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Novo Nordisk axes experimental obesity drugs after success with later-stage meds
Fierce Biotech
Novo Nordisk
obesity
semaglutide
Flag link:
Biopharma takeovers show quantity, if not quality
Biopharma takeovers show quantity, if not quality
EP Vantage
COVID-19
pandemic
M&A
Novo Nordisk
Corvidia
Gilead Sciences
Pionyr
Alexion
Portola Pharmaceuticals
Menarini
Stemline Therapeutics
Shionogi
Tetra Therapeutics
Flag link:
Mylan, seeking to market Victoza generic, convinces panel to start up patent review
Mylan, seeking to market Victoza generic, convinces panel to start up patent review
Fierce Pharma
Mylan
patents
generics
Novo Nordisk
Victoza
diabetes
Flag link:
ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
ADA: Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data show
Fierce Pharma
ADA
diabetes
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Flag link:
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
Fierce Pharma
ADA
diabetes
Novo Nordisk
insulin icodec
Sanofi
Lantus
insulin
Flag link:
Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Novo Nordisk Strikes a $725M Deal for AstraZeneca Spinout Corvidia
Xconomy
Novo Nordisk
M&A
Corvidia
kidney disease
Flag link:
Big pharma heads towards important readouts
Big pharma heads towards important readouts
EP Vantage
Ozempic
Novo Nordisk
etrolizumab
Roche
Ipatasertib
finerenone
Bayer
filgotinib
Gilead Sciences
Galapagos
Avalglucosidase alfa
Sanofi
Rinvoq
AbbVie
clinical trials
Flag link:
Novo's diabetes drug also appears to work in NASH
Novo's diabetes drug also appears to work in NASH
BioPharma Dive
Novo Nordisk
NASH
semaglutide
Flag link:
Sidelined by COVID-19 pandemic, Team Novo Nordisk cyclists crank and jam on social media instead
Sidelined by COVID-19 pandemic, Team Novo Nordisk cyclists crank and jam on social media instead
Fierce Pharma
Novo Nordisk
pharma marketing
social media
Flag link:
The top pharma companies in social media
The top pharma companies in social media
Fierce Pharma
social media
Boehringer Ingelheim
AbbVie
GSK
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Flag link:
Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma
Genentech, Novo Nordisk and AbbVie top the list of best workplaces in biopharma
Fierce Pharma
Roche
Genentech
Novo Nordisk
AbbVie
Fortune
employees
Flag link:
Will Novo’s big thinking in obesity pay off?
Will Novo’s big thinking in obesity pay off?
EP Vantage
Novo Nordisk
obesity
Ozempic
AM833
clinical trials
Flag link:
Novo Nordisk expands 90-day free insulin program to workers affected by COVID-19
Novo Nordisk expands 90-day free insulin program to workers affected by COVID-19
Fierce Pharma
Novo Nordisk
insulin
diabetes
COVID-19
Flag link:
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Novo Nordisk Pauses 3 Clinical Trials Testing Hemophilia Therapy
Xconomy
Novo Nordisk
clinical trials
concizumab
hemophilia
Flag link:
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Insights into how Novo Nordisk's Saxenda cuts food cravings may inspire new obesity drugs
Fierce Biotech
Novo Nordisk
Saxenda
obesity
food cravings
Flag link:
Novo bids for recognition in the year of NASH
Novo bids for recognition in the year of NASH
EP Vantage
NASH
Novo Nordisk
Ozempic
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
How a cocktail of existing drugs could regenerate insulin-producing cells in diabetes
Fierce Biotech
diabetes
insulin
Mt Sinai
Novo Nordisk
Ozempic
Rybelsus
Victoza
Eli Lilly
Trulicity
AstraZeneca
Bydureon
Flag link:

Pages